spot_img
Monday, August 15, 2022
More
    HomeHealthBiogen offers a disappointing financial outlook for 2022

    Biogen offers a disappointing financial outlook for 2022

    -



    Sales of Aduhelm, Biogen’s remedy for Alzheimer’s illness, continued to underperform expectations within the fourth quarter, Biogen stated Thursday, main the corporate to subject a disappointing monetary forecast for 2022.

    Aduhelm accounted for $1 million in income within the ultimate three months of 2021, depressed by continued doubts concerning the drug’s profit for sufferers and restrictions positioned on its use by insurance coverage firms. Analysts who cowl Biogen had been anticipating the corporate to ship $2 million in Aduhelm gross sales throughout the fourth quarter.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,436FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts